Investors in Anthera Pharmaceuticals, Inc. (ANTH - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the April 21 st, 2017, $1 Call had some of the highest implied volatility of …
ZACKS2mon
Media headlines about Anthera Pharmaceuticals (NASDAQ:ANTH) have trended very positive recently, Alpha One Sentiment Analysis reports. The research firm, a service of Accern, identifies negative and positive news coverage by …
Anthera Pharmaceuticals Inc.
SL Industries (SLI): SLI stock is up 13.99% today. Anthera Pharmaceuticals (ANTH): ANTH stock is up 9.76% today. Silicon Graphics International Corp (SGI): SGI stock is up 11.35% today. Dipexium Pharmaceuticals Llc (DPRX): DPRX …
Anthera Pharmaceuticals, Inc. ANTH has been on the move lately as the stock has risen by 22.1% in the past four weeks, and it is currently trading well above its 20-Day SMA. This is a pretty solid move higher, but the question that has to be …
Anthera Pharmaceuticals, Inc. ANTH announced disappointing top-line data from a phase III study - SOLUTION - on one of its pipeline candidates, Sollpura (liprotamase), in cystic fibrosis patients with exocrine pancreatic insufficiency (EPI). …
NASDAQ4mon
Anthera Pharmaceuticals Inc. (ANTH) said its pancreatic enzyme replacement drug ... Following the news, Anthera stock price jumped 24% during pre-market hours on Thursday morning. (See also, 5 Things to Know Before Buying Anthera …
ETFs by nature are passive index-followers, so as long as the stock remains in the index, it doesn't much matter whether analysts find the stock overvalued or undervalued. Below are some of the ETFs that hold ANTH at last report:
Target
Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) today announced the pricing of an underwritten public offering of 30,000,000 shares of its common stock at a price of $0.50 per share and two tranches of warrants to purchase an …
Anthera Pharmaceuticals is having an overwhelmingly rough day in the market today. After announcing a public offering in the after-hours yesterday, the stock went on a steep dive, causing it to open on an exceptionally low note today. …
Anthera Pharmaceuticals Inc.
Zacks Investment Research upgraded shares of Anthera Pharmaceuticals Inc (NASDAQ:ANTH) from a hold rating to a strong-buy rating in a report issued on Wednesday. The brokerage currently has $0.75 price target on the …
Breeze1mon